Literature DB >> 22348828

Design, synthesis, theoretical calculations and biological evaluation of new non-symmetrical choline kinase inhibitors.

Belén Rubio-Ruíz1, Ana Conejo-García, Pablo Ríos-Marco, María Paz Carrasco-Jiménez, Josefa Segovia, Carmen Marco, Miguel A Gallo, Antonio Espinosa, Antonio Entrena.   

Abstract

Inhibition of Choline Kinase (ChoK) has been reported as a therapeutical target in the treatment of some kinds of tumor. In this paper, the design and synthesis of new non-symmetrical monocationic ChoK inhibitors is described, bearing a cationic head and an adenine moiety connected by linkers of different lengths. Docking studies indicate that the cationic head of these compounds could be inserted into the choline binding site of the enzyme, while the adenine moiety could be stabilized into the ATP binding site. Docking studies also support the difference of activity of the synthesized compounds, which depends on both the substituent at position 4 of the cationic head and the linker length, being dimethylamine and 1,4-diphenylbutane respectively, the most appropriate ones. Compounds 14 (IC(50) = 10.70 ± 0.40 μM) and 17 (IC(50) = 6.21 ± 0.97 μM) are the most potent ChoK inhibitors and suitable for further modification with a view to obtain more potent antitumor compounds. Copyright Â
© 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22348828     DOI: 10.1016/j.ejmech.2012.01.050

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  6 in total

1.  A new family of choline kinase inhibitors with antiproliferative and antitumor activity derived from natural products.

Authors:  A Estévez-Braun; A G Ravelo; E Pérez-Sacau; J C Lacal
Journal:  Clin Transl Oncol       Date:  2014-12-04       Impact factor: 3.405

2.  Choline kinase inhibitors EB-3D and EB-3P interferes with lipid homeostasis in HepG2 cells.

Authors:  Alberto Sola-Leyva; Luisa C López-Cara; Pablo Ríos-Marco; Antonio Ríos; Carmen Marco; María P Carrasco-Jiménez
Journal:  Sci Rep       Date:  2019-03-25       Impact factor: 4.379

3.  Anticancer Activity of the Choline Kinase Inhibitor PL48 Is Due to Selective Disruption of Choline Metabolism and Transport Systems in Cancer Cell Lines.

Authors:  Pablo García-Molina; Alberto Sola-Leyva; Pilar M Luque-Navarro; Alejandro Laso; Pablo Ríos-Marco; Antonio Ríos; Daniela Lanari; Archimede Torretta; Emilio Parisini; Luisa C López-Cara; Carmen Marco; María P Carrasco-Jiménez
Journal:  Pharmaceutics       Date:  2022-02-16       Impact factor: 6.321

4.  Design of symmetrical and nonsymmetrical N,N-dimethylaminopyridine derivatives as highly potent choline kinase alpha inhibitors.

Authors:  Sebastian Trousil; Laurence Carroll; Andrew Kalusa; Ola Aberg; Maciej Kaliszczak; Eric O Aboagye
Journal:  Medchemcomm       Date:  2013-04-01       Impact factor: 3.597

5.  Design, synthesis, crystallization and biological evaluation of new symmetrical biscationic compounds as selective inhibitors of human Choline Kinase α1 (ChoKα1).

Authors:  Santiago Schiaffino-Ortega; Eleonora Baglioni; Elena Mariotto; Roberta Bortolozzi; Lucía Serrán-Aguilera; Pablo Ríos-Marco; M Paz Carrasco-Jimenez; Miguel A Gallo; Ramon Hurtado-Guerrero; Carmen Marco; Giuseppe Basso; Giampietro Viola; Antonio Entrena; Luisa Carlota López-Cara
Journal:  Sci Rep       Date:  2016-03-31       Impact factor: 4.379

6.  Plasmodium falciparum Choline Kinase Inhibition Leads to a Major Decrease in Phosphatidylethanolamine Causing Parasite Death.

Authors:  Lucía Serrán-Aguilera; Helen Denton; Belén Rubio-Ruiz; Borja López-Gutiérrez; Antonio Entrena; Luis Izquierdo; Terry K Smith; Ana Conejo-García; Ramon Hurtado-Guerrero
Journal:  Sci Rep       Date:  2016-09-12       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.